Gross Proceeds of All Three Offerings of 10 Million Common Shares in Total Aggregate to USD 117.5 Million
Lausanne, Switzerland, July 31, 2018 - AC Immune, SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced the closing of its previously announced second subscription rights offering to eligible shareholders to subscribe for 1,500,000 newly issued common shares at a price per common share of USD 11.75, for gross proceeds of USD 17.6 million. As previously announced, on July 23, 2018, AC Immune closed its first subscription rights offering and registered public offering of 8,500,000 of its common shares at an offering price of USD 11.75 per share for aggregate gross proceeds of USD 99.9 million, bringing aggregate gross proceeds for all three offerings to USD 117.5 million.
The second subscription rights offering was made pursuant to an effective shelf registration statement of the Company previously filed with the U.S. Securities and Exchange Commission. This offering was made only by means of a prospectus supplement and the accompanying prospectus. Copies of the prospectus for this offering may be obtained from the Company in writing at AC Immune SA, EPFL Innovation Park Building B, 1015 Lausanne, Switzerland or via telephone by calling +41 21 345 91 21.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is not a prospectus within the meaning of article 652a of the Swiss Code of Obligations, nor is it a listing prospectus of any exchange or regulated trading facility in Switzerland. Copies of this press release may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law.
About AC Immune
AC Immune is a clinical-stage Swiss-based biopharmaceutical company, listed on Nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins.
For further information, please contact:
| In Europe |
AC Immune Corporate Communications
Phone: +41 21 345 91 34
| In the US |
AC Immune Investor Relations
Phone: +1 970 987 26 54
| Nick Miles/Toomas Kull |
Cabinet Privé de Conseils s.a.
Phone: +41 22 552 46 46
| Ted Agne |
The Communications Strategy Group Inc.
Phone: +1 781 631 3117